- Home
- FENC vs SABA Comparison
FENC vs SABA Comparison
Compare FENC & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- SABA
- Stock Information
- Founded
- FENC 1996
- SABA 1988
- Country
- FENC United States
- SABA United States
- Employees
- FENC N/A
- SABA N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- SABA
- Sector
- FENC Health Care
- SABA
- Exchange
- FENC Nasdaq
- SABA Nasdaq
- Market Cap
- FENC 225.4M
- SABA 257.3M
- IPO Year
- FENC 2001
- SABA N/A
- Fundamental
- Price
- FENC $8.67
- SABA $9.16
- Analyst Decision
- FENC Strong Buy
- SABA
- Analyst Count
- FENC 2
- SABA 0
- Target Price
- FENC $13.50
- SABA N/A
- AVG Volume (30 Days)
- FENC 54.7K
- SABA 290.0K
- Earning Date
- FENC 11-06-2025
- SABA 01-01-0001
- Dividend Yield
- FENC N/A
- SABA 12.91%
- EPS Growth
- FENC N/A
- SABA N/A
- EPS
- FENC N/A
- SABA N/A
- Revenue
- FENC $33,302,000.00
- SABA N/A
- Revenue This Year
- FENC $0.96
- SABA N/A
- Revenue Next Year
- FENC $51.71
- SABA N/A
- P/E Ratio
- FENC N/A
- SABA N/A
- Revenue Growth
- FENC N/A
- SABA N/A
- 52 Week Low
- FENC $3.96
- SABA $3.64
- 52 Week High
- FENC $9.42
- SABA $4.42
- Technical
- Relative Strength Index (RSI)
- FENC 48.27
- SABA 43.67
- Support Level
- FENC $8.96
- SABA $9.13
- Resistance Level
- FENC $9.13
- SABA $9.23
- Average True Range (ATR)
- FENC 0.28
- SABA 0.09
- MACD
- FENC -0.02
- SABA -0.01
- Stochastic Oscillator
- FENC 17.88
- SABA 13.00
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.